Pacific Biosciences Of California (PACB) EBIT Growth (1y) (2011 - 2026)
Pacific Biosciences Of California (PACB) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | -17.50% |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | 49.06% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 30.43% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 43.83% |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | 24.81% |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | 49.72% |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | 13.00% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 57.74% |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | 16.18% |
| 10 | Pacific Biosciences Of California | 394.53 Mn | 157.66 Mn | 12.64 Mn | 0.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.54% |
| Mar 31, 2026 | 98.05% |
| Dec 31, 2025 | 73.08% |
| Sep 30, 2025 | 39.33% |
| Jun 30, 2025 | 74.49% |
| Mar 31, 2025 | -427.19% |
| Dec 31, 2024 | -74.79% |
| Sep 30, 2024 | 22.32% |
| Jun 30, 2024 | -140.31% |
| Mar 31, 2024 | 10.84% |
| Dec 31, 2023 | -0.53% |
| Sep 30, 2023 | -10.55% |
| Jun 30, 2023 | -7.66% |
| Mar 31, 2023 | -17.71% |
| Dec 31, 2022 | -34.65% |
| Jun 30, 2022 | -80.90% |
| Mar 31, 2022 | -129.97% |
| Dec 31, 2021 | -169.74% |
| Jun 30, 2021 | -59.72% |
| Mar 31, 2021 | -3.06% |